In CLL, ZA was not an ideal chemosensitizing agent since it inhibited Ras/ERK1–2 and RhoA/RhoA kinase signaling pathways, HIF-1α activity, and MDR1 expression, but did not increase Doxo-induced cytotoxicity. Here, RHOA is linked to B-cell chronic lymphocytic leukemia.